
    
      This is a 2-part study with each part is an open-label, crossover study in healthy adult
      subjects.

      Total 56 subjects will be enrolled into the study and divided into 2 part (Part A and Part
      B), 28 subjects in each part. Part A is to evaluate the drug-interaction between GLS4/RTV and
      ETV, Part B is to evaluate the drug-interaction between GLS4/RTV and TDF. With each part, the
      subject will be split into two groups and receive study drug per the defined treatment
      periods of Day 1, Day 11-20 and Day 21.
    
  